Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for TAZVERIK® (tazemetostat) has been granted conditional approval in China for the treatment of ...

Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three ... or refractory follicular lymphoma and the further clinical ...

An extraordinary rescue operation nears its end, as two children from Gaza arrive in the US for cancer treatment.

Cancer is one of the leading causes of death in dogs, with diagnosis ranging from lymphoma to mast cell tumors. A recent trend in pet care among owners is ...

A Trump executive order forming the commission tasked them with assessing the ‘threat posed by’ ADHD meds. Learn how experts ...

A significant study detailing OncoSeek®'s efficacy was published in eClinicalMedicine, a clinical journal of The Lancet, titled A panel o ...

Tax cuts for everyone, more energy bill relief and cheaper medicines are the key selling points of Jim Chalmers’ ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we”) ...

Democrats do not want to repeat the mistakes of last week, when they split over the GOP's stopgap measure to avoid a federal ...

U.S. commercial launch progressing on track with 33 authorized treatment centers as of March 19, 2025, following US FDA approval on November 8, 2024Obe-cel MHRA and EMA marketing authorizations ...